The Eli Lilly-backed immuno-oncology product developer floated at the top of its range, with Bluebird Bio investing $10m.

Partly based on Columbia University research, Modis is advancing treatments for rare diseases caused by dysfunction in cellular mitochondria.

Immunotherapy developer Sutro Biopharma has floated on the Nasdaq Global Market, providing exits for Merck & Co, Celgene, Amgen and Eli Lilly.

Sutro Biopharma, an immunotherapy developer commercialising technology created at Stanford University, has floated on the Nasdaq Global Market.

University of Rochester-affiliated VC fund Excell Partners has been selected to manage a state government-funded vehicle targeting local companies in sectors such as optics and life sciences.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

The diabetes diagnosis technology developer harnessed Heritage Provider Network and Optum Ventures for its latest round.

Fosun Pharma has contributed to a $250m series D round for medical device maker Butterfly Network, valuing the company at $1.25bn.

Novo has co-led a series B round together with Omega Funds for Morphic Therapeutic, based on research by Harvard professor Timothy Springer.

The Astra Zeneca antibiotic development spin off has floated in an initial public offering in which Novo bought more than $16m in shares.